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Abstract
Background: Detection of Ureaplasma, Mycoplasma and Candida spp. in the vagina during pregnancy has previously
been associated with preterm birth (PTB). However, the prevalence of these microorganisms and the associated obstetric
risks (likely to be population-specific) have not been determined in Australian women; furthermore, in the case
of Ureaplasma spp., very few studies have attempted characterisation at the species level and none have examined
genotype/serovar status to further refine risk assessment.
Methods: In order to address these issues we sampled the vaginal fluid of 191 pregnant Australian women at
three time points in pregnancy. Culture methods were used for detection of Ureaplasma spp. and Candida spp.,
and real-time PCR was used for speciation of U. parvum and U. urealyticum, non-albicans Candida spp., Mycoplasma
hominis and Mycoplasma genitalium. High-resolution melt PCR was used to genotype U. parvum. Data on
various lifestyle factors (including sex during pregnancy and smoking), antimicrobial use and pregnancy outcome were
collected on all participants. Chi-square tests were used to assess the association of vaginal microorganisms with PTB.
Results: Detection of Ureaplasma spp. was higher among spontaneous PTB cases, specifically in the presence of
U. parvum [77 % preterm (95 % confidence interval (CI) 50–100 %) vs. 36 % term (CI: 29–43 %), p = 0.004], but
not U. urealyticum. The association with PTB strengthened when U. parvum genotype SV6 was detected (54 %
preterm (CI: 22–85 %) vs. 15 % term (CI: 10–20 %), p = 0.002); this genotype was also present in 80 % (4/5) of
cases of PTB <34 weeks gestation. When present with Candida albicans in the same sample, the association
with PTB remained strong for both U. parvum [46 % preterm (CI: 15–78 %) vs. 13 % term (CI: 8–18 %), p = 0.005]
and U. parvum genotype SV6 [39 % preterm (CI: 8–69 %) vs. 7 % term (CI: 3–11 %), p = 0.003]. With the
exception of Candida glabrata, vaginal colonisation status for all organisms was stable throughout pregnancy.
Smoking significantly increased the likelihood of detection of all target organisms.
Conclusions: These data suggest that the presence of different species and serovars of Ureaplasma spp. in the
vagina confers an increased risk of spontaneous PTB, findings which may be useful in risk assessment for identifying
women who would benefit from antimicrobial treatment.
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Background
The role of human genital Ureaplasmas (Ureaplasma par-
vum and Ureaplasma urealyticum) and Mycoplasmas
(Mycoplasma hominis and Mycoplasma genitalium) in pre-
term birth (PTB) has been a contentious topic that has re-
sulted in considerable research over the past two decades.
A recent review article by Capoccia et al. [1], summarizing
the bulk of this research effort (with the exception of M.
genitalium), showed that the majority of studies with de-
fined case/control subjects found an association with nega-
tive pregnancy outcomes, especially for Ureaplasma spp.
For M. hominis, this association appeared to be increased
when detected alongside Ureaplasma spp. [1]. M. genita-
lium, however, is more commonly associated with pelvic in-
flammatory disease [2] and has also been linked to bacterial
vaginosis (BV) [3]. Vaginal colonisation by Candida spp., a
common yeast synonymous with vaginal thrush, has also
been associated with PTB risk [4–7].
However, it is still unclear why some women who are
asymptomatically colonised with these organisms have
pregnancies that deliver preterm while others deliver at
term; possible explanations include interactions with
other microorganisms and inflammatory modulators,
the timing and duration of colonisation, differences in
virulence between species/strains, and eradication or
exacerbation via maternal immune responses. With re-
spect to Ureaplasma spp., very few studies have ever
attempted to refine the data beyond the genus level,
despite evidence that numerous other Ureaplasma-
associated disease phenotypes are differentially associ-
ated with U. urealyticum and not U. parvum [8–12].
Further to this, to the best of our knowledge, no studies
have ever looked at the relationship that may exist be-
tween PTB and the presence of specific Ureaplasma
spp. genotypes (serovars). In addition, few studies have
looked at the effect of combined colonisation with
these organisms, with most studies instead focusing on
either Ureaplasma spp. and M. hominis (and not M.
genitalium) or Candida spp.
PTB is now recognised as the leading cause of death
in children under the age of 5 years in the developed
world [13], with intrauterine infection being causally as-
sociated with ~40 % of all PTBs [14]. In particular, the
births of the earliest gestational ages, which are associ-
ated with the greatest mortality and morbidity, are much
more likely to be the consequence of intrauterine infec-
tion and/or inflammation (up to 80 %). There is, there-
fore, a need to be able to predict which women are at a
high risk of PTB, based on factors other than previous
clinical history alone, so that appropriate treatment may
be provided to those who would benefit. This is espe-
cially relevant for women in their first pregnancy. Des-
pite the body of research that has been conducted into
the presence and significance of genital Ureaplasma,
Mycoplasma and Candida spp. colonisation during preg-
nancy, there is very little information available on the re-
lationship between specific lifestyle practices, such as
smoking and sexual activity, and vaginal colonisation.
However, it has been well established that tobacco use
increases susceptibility to bacterial infection [15] and a
strong association has been documented between smok-
ing and BV [16–19]. Furthermore, some genital Urea-
plasma and Mycoplasma spp. are deemed to be sexually
transmitted infections [20].
In addition, the vast majority of previous studies that
have looked at genital Ureaplasma, Mycoplasma and
Candida spp., have focused on collection of clinical
samples at a single time point. This approach provides
no data on the colonisation dynamics of a particular or-
ganism and this is likely to be of significance in terms of
implementing diagnostic assays for the detection of
women at risk of PTB. It is highly likely that all of the
above information combined, will not only increase our
understanding of these organisms during pregnancy, but
importantly, will allow us to establish useful microbial
biomarkers. These, combined with patient-specific quali-
tative data, will improve our ability to predict women at
an increased risk of PTB who would benefit from anti-
microbial treatment. Due to previous descriptions of
variation in the vaginal microbiota as a result of ethnic,
cultural and social factors [21], it is likely that microbial
colonisation status and PTB risk are strongly
population-dependent.
The aims of this study, therefore, were to document the
presence of U. parvum (including genotype analysis), U.
urealyticum, C. albicans, C. glabrata, other non-albicans
Candida spp., M. hominis and M. genitalium in the vagina
of a cohort of asymptomatic pregnant Australian women at
three time points during pregnancy, and to examine any as-
sociation between their microbiological characteristics, a
range of lifestyle factors, and risk of PTB.
Methods
Subjects
The study consisted of 206 low-risk pregnant women
recruited from King Edward Memorial Hospital
(KEMH), Perth, Western Australia. Fifteen cases with-
drew from the study or were lost to follow-up, leaving
191 for analysis. The study was approved by the
Human Research Ethics Committee of the Western
Australian Department of Health, Women and Newborn
Health Service (2056/EW).
Inclusion and exclusion criteria
Women with a singleton pregnancy were eligible for in-
clusion if they were aged 18–40 years, able to speak and
read English and were pregnant within the first or
second trimester.
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Women were excluded from the study if they were
deemed to be at a high risk of PTB (one or more previ-
ous PTBs) and/or other pregnancy complications such
as preeclampsia. Other exclusion criteria included
current use of antifungals, tetracycline and/or macrolide
antibiotics, current diagnosis of a urinary tract infection,
and history of recurrent vaginal thrush.
Questionnaires
Upon recruitment to the study and at each subsequent
sampling point, women were invited to complete a de-
identified medical/lifestyle questionnaire in a private set-
ting. The questionnaire first inquired about medications
currently used (antibiotic/natural/probiotic) and past
diagnoses of urinary tract infections/vaginal thrush. In-
formation regarding current and previous smoking and/
or alcohol use was sought as ‘yes or no’, and subse-
quently followed by questions to quantify the number of
cigarettes smoked/standard drinks consumed each day
as appropriate. The average number of episodes of
sexual intercourse per week during pregnancy was
recorded.
Pregnancy outcome data
Pregnancy outcome data from the hospital’s electronic
medical records were accessed by experienced research
midwives and coded after completion of the pregnancy.
Sample collection
Written informed consent was obtained by the attending
midwife prior to enrolment in the study. This included
consenting to publication of any data produced by the
study. Participants provided two self-collected vaginal
swabs (Copan Diagnostics, Murrieta, CA, USA) at recruit-
ment (median 21 week, range 13–26 weeks gestational age
[GA]), ~28 weeks GA (median 29, range 24–38 weeks)
and ~36 weeks GA (median 36, range 32–40 week). The
first swab was employed for detection of Ureaplasma and
Mycoplasma spp. and the second for detection of Candida
spp. Detailed verbal, written and pictorial instructions
were provided to all women in an attempt to standardise
the swab collection process. Briefly, while wearing gloves,
participants inserted the swab 5 cm into their vagina and
gently rotated this for 20 s, ensuring the walls of the va-
gina came into contact with the swab. Swabs were then
immediately placed into a collection tube containing
either 1 mL UTM media (Ureaplasma and Mycoplasma
spp.) (Copan Diagnostics) or 2 mL of CAT media
(Candida spp.) (Copan Diagnostics), snapped at the mid-
stem breakpoint, capped and stored at 4 °C. All samples
were transported to the laboratory on ice for culture
within 24 h of collection.
Detection of Ureaplasma spp.
Culture
UTM tubes were vortexed for 10 s to release all cells
from swabs. Swabs were subsequently pressed against
the tube wall to release all free liquid and then dis-
carded. Two hundred microliters of sample was added
to 1.8 mL of 10B broth (Melbourne University Media
Preparation Unit) and incubated for 48 h at 37 °C, 5 %
CO2, 2 % O2. The remaining volume of sample was
transferred to a 2 mL microfuge tube and frozen at
−80 °C until DNA extraction.
Positive cultures, indicated by a pH-associated colour
change (yellow > pink), were immediately transferred to
2 mL microfuge tubes and frozen at −80 °C.
DNA extraction
DNA was extracted from 250 μL of UTM swab eluate
using the Siemens Sample Preparation Kit 1.0 (Siemens,
Munich, Germany) on an automated Kingfisher Duo ex-
traction platform (Thermo Fisher Scientific Inc. MA,
USA) as per manufacturer’s instructions. All extracts
were eluted in a final volume of 100 μL of elution buffer
(Siemens). A positive extraction control consisting of ap-
proximately 250 colour changing units (CCU) each of U.
parvum and U. urealyticum was included in all runs.
Real-time PCR
In addition to culture, Ureaplasma spp. DNA was de-
tected from vaginal swabs using real-time PCR. Vaginal
swab DNA was screened using an assay targeting the
urease gene of U. parvum and U. urealyticum, as de-
scribed by Yi et al. [22], adapted for use on a ViiA7 real-
time PCR system (Life Technologies, Carlsbad, CA,
USA). Reaction mixtures (final concentration) consisted
of 1X Taqman FAST Advanced Master Mix (Life Tech-
nologies), 0.9 μM primers UU1613F and UU1524R (Life
Technologies), 0.25 μM probes UU-parvo (FAM) and
UU-T960 (VIC) (Life Technologies), 5 μL of template
DNA and nuclease-free water (Ambion, Life Technologies)
to a final volume of 20 μL. PCR cycling conditions con-
sisted of an initial denaturation/Taq activation at 95 °C for
20 s, followed by 40 quantification cycles of 95 °C for 1 s
and 60 °C for 20 s (data acquiring). Positive standards were
included in each run.
High-resolution melt PCR
Samples that were positive for U. parvum DNA were geno-
typed and classified as either serovar (SV) one, SV3, SV6 or
SV14 using our previously described high resolution melt
(HRM) PCR assay targeting the multiple-banded antigen
gene [23] on a ViiA7 real-time PCR system (Life Technolo-
gies). Reaction mixtures (final concentration) consisted of
1X Amplitaq Gold 360 buffer (Life Technologies), 1.5 mM
MgCl2 (Life Technologies), 200 μM of each dNTP
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(Life Technologies), 0.3 μM primers UPHRM-F and
UPHRM-R (Life Technologies), 1X MeltDoctor HRM
dye (Life Technologies), Amplitaq Gold 360 DNA
polymerase (0.1 U/μL) (Life Technologies), 10 μL of
template DNA and nuclease-free water (Ambion, Life
Technologies) to a final volume of 20 μL. PCR cycling
conditions consisted of an initial denaturation/Taq ac-
tivation at 95 °C for 10 min, followed by 40 cycles of
95 °C for 15 s and 60 °C for 1 min (data acquiring). To
provide data on U. parvum serovar status, amplicons
were subsequently subject to a HRM step where the
temperature was raised to 95 °C for 10 s and then low-
ered to 60 °C for 1 min. The temperature was then
raised to 95 °C at a rate of 0.025 °C/s (continuous data
acquisition), held at 95 °C for 15 s and then lowered
to 60 °C for 15 s. HRM profiles were analysed using
ViiA7 real-time PCR system software v1.2.1 (Life
Technologies). All samples were run in duplicate and
positive standards of U. parvum SV1, SV3, SV6 and
SV14 were included in each run.
Sequencing
Following HRM analysis, samples that produced non-
standard melt curve patterns were subject to DNA se-
quencing. PCR amplicons were generated using the
same HRM primer set on a Veriti PCR thermocycler
(Life Technologies). Reaction mixtures (final concentra-
tion) consisted of 1X Amplitaq Gold 360 buffer (Life
Technologies), 2.0 mM MgCl2 (Life Technologies),
200 μM of each dNTP (Life Technologies), 0.5 μM
primers UPHRM-F and UPHRM-R (Life Technologies),
Amplitaq Gold 360 DNA polymerase (1.25U) (Life Tech-
nologies), 5 μL of template DNA and nuclease-free water
(Ambion, Life Technologies) to a final volume of 50 μL.
PCR cycling conditions consisted of an initial denatur-
ation/Taq activation at 95 °C for 10 min, followed by
40 cycles of 95 °C for 15 s, 56 °C for 30 s and 72 °C for
45 s. A final extension step of 72 °C for 7 min was also
included.
PCR amplicons were checked for size (305 bp) on a 1.5 %
agarose gel stained with Gel Red (Biotium) and subse-
quently purified using a QIAquick PCR purification kit
(QIAGEN) as per manufacturer’s instructions. Purified
DNA fragments were sequenced using Big Dye version 3.1
chemistry (Applied Biosystems) and post-cleaned using
SPRI. Fragments were separated on a 3730xI DNA Ana-
lyser using a 96-capillary array (Applied Biosystems) at the
Australian Genome Research Facility (Perth, Western
Australia).
Detection of Mycoplasma spp.
DNA extraction
DNA was extracted from 250 μL of UTM swab eluate as
described above.
Real-time PCR
Mycoplasma hominis M. hominis DNA was detected in
vaginal swabs using real-time PCR. DNA samples were
screened using an assay targeting the yidC gene of M.
hominis as described by Ferandon et al. [24], adapted for
use on a ViiA7 real-time PCR system (Life Technolo-
gies). Reaction mixtures (final concentration) consisted
of 1X Taqman FAST Advanced Master Mix (Life Tech-
nologies), 0.9 μM primers MHyidCfwd and MHyidCrev
(Life Technologies), 0.25 μM probe MHyidC (FAM) (Life
Technologies), 5 μL of template DNA and nuclease-free
water (Ambion, Life Technologies) to a final volume of
20 μL. PCR cycling conditions were as described for
Ureaplasma spp. A positive standard was included in
each run.
Mycoplasma genitalium M. genitalium DNA was de-
tected in vaginal swabs using real-time PCR. DNA sam-
ples were screened using an assay targeting the MgPa
gene of M. genitalium as described by Jensen et al. [25],
adapted for use on a ViiA7 real-time PCR system (Life
Technologies). Reaction mixtures (final concentration)
consisted of 1X Taqman FAST Advanced Master Mix
(Life Technologies), 0.9 μM primers MgPa-355F and
MgPa-432R (Life Technologies), 0.25 μM probe MgPa-
380 (VIC) (Life Technologies), 7.9 μL of template DNA
and nuclease-free water (Ambion, Life Technologies) to
a final volume of 20 μL. PCR cycling conditions con-
sisted of an initial denaturation/Taq activation at 95 °C
for 20 s, followed by 50 quantification cycles of 95 °C for
1 s and 60 °C for 20 s (data acquiring). Positive stan-
dards were included in each run.
Detection of Candida spp.
Culture
CAT tubes were vortexed for 10 s to release all cells
from swabs. Swabs were subsequently pressed against
the tube wall to release all free liquid and then disposed
of. One millilter of sample was transferred to a 2 mL
microfuge tube and frozen at −80 °C until DNA extrac-
tion. The remaining sample (approximately 900 μL) was
incubated at 37 °C for 24 h to enrich for low cell titres
of Candida spp. Following incubation, two 10 μL loops
of sample were plated onto Candida Brilliance agar
(Oxoid, Thebarton, South Australia, Australia) and incu-
bated at 37 °C for 72 h.
Positive cultures on Candida Brilliance agar (Oxoid) were
classified as follows: Green colonies = C. albicans; pink/
yellow/beige/brown colonies = non-albicans Candida
spp. All positive cultures were re-plated for purity and
following incubation, pure cultures were re-suspended
in 2 mL of Sabaraud-Dextrose broth (Oxoid) and
frozen at −80 °C.
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DNA extraction
DNA was extracted from 250 μL of pure Candida sp.
isolate broth resuspension as described above.
Real-time PCR
To confirm the identification of non-albicans Candida spp.
isolated using Candida Brilliance agar, a multiplex real-time
PCR assay targeting the RNase P RNA (RPR) gene of
Candida sp. and C. glabrata was used. Primer and probe
designs were similar to that of Innings et al. [26], but were
optimised for use on a ViiA7 real-time PCR system (Life
Technologies). Reaction mixtures (final concentration) con-
sisted of 1X Taqman FAST Advanced Master Mix (Life
Technologies), 0.9 μM primers CAND-CR1F (5′ CGG
GTGGGAAATTCGGT 3′), CAND-CR5R (5′ CAATGAT
CGGTATCGGGT 3′), GLA-F (5′ TGGCTCACACAC
TTTGTCACTTT 3′) and GLAR (5′ ACCTCGCCTCAC
ACCAATG 3′) (Life Technologies), 0.25 μM probes ALL-
CAN (NED-TTCGCATATTGCACTMAAYAGC-MGB)
and GLA (VIC-AACCTGCCATTTCCGCTCCCTTAA
GA-TAMRA) (Life Technologies), 5 μL of template DNA
and nuclease-free water (Ambion, Life Technologies) to a
final volume of 20 μL. PCR cycling conditions were as de-
scribed above for Ureaplasma spp.
Statistical analyses
Data were summarised using frequency distributions for
categorical data, and median, interquartile range and
range for continuous data. Categorical outcomes were
compared using Chi-square and Fisher’s exact tests, and
continuous outcomes compared using Mann-Whitney
tests. All analyses were conducted on detection of mi-
crobes at recruitment, due to the relatively stable colon-
isation levels throughout pregnancy. SPSS Version 20.0
(Armonk, NY: IBM Corp) statistical software was used




206 women in total were recruited to the study. From
these, 15 withdrew or were lost to follow-up. Demo-
graphic/birth and lifestyle characteristics of the 191
women that formed the final study cohort are provided
below (Table 1). The overall PTB rate (<37 weeks GA)
was 9 %, which included 13 spontaneous births and four
births that required labour induction or caesarean deliv-
ery for maternal or fetal indications. These four births
were excluded in the comparison of microorganisms be-
tween preterm and term births. There were six births
(five spontaneous) <34 weeks GA (3 %) and two births
with a birth weight <1500 g (1 %).
Detection of vaginal Ureaplasma, Mycoplasma and
Candida spp. during pregnancy
Vaginal detection rates for Ureaplasma spp., Myco-
plasma spp. and Candida spp. varied substantially at
both the genus and species level (Table 2). Ureaplasma
spp. were the most common of the three organisms de-
tected, present in 44–48 % of women over the three
sampling points. Within this genus, U. parvum was the
most common species detected, 3–4 times more preva-
lent than U. urealyticum (Table 2).
Candida spp. were the second most common organ-
ism detected, present in 34–38 % of women. Within this
genus, C. albicans was by far the most common species
detected, 6–25 and 10–24 times more prevalent than C.
glabrata and non-albicans/non-glabrata Candida spp.,
respectively (Table 2).
Table 1 Demographic, birth and lifestyle characteristics of
women in the studya
Demographic and birth n = 191
Maternal age (y) 30 (26–33;18–43)
Caucasian 119 (62 %)
GA at birth 39 (38–40; 26–42)
GA <37 weeks 17 (9 %)
Birthweight (g) 3435 (3080–3733;690–4794)
Gender male 92 (48 %)
Lifestyle and medication n = 189
Current antibiotic, antifungal or
probiotic medication
8 (4 %)
UTI diagnosis ever 75 (40 %)
Thrush diagnosis ever 91 (48 %)
Thrush > 2 times 12 (13 %)
Current smoker 21 (11 %)
Smoke >10/day 5 (3 %)
Previous smoker 50 (27 %)
Smoke >10–20/day 13 (7 %)
Smoke >20/day 5 (3 %)
Current alcohol 4 (2 %)
≥ 5 drinks/week 1 (0.5 %)
Previous alcohol 108 (57 %)
< 1 drink/week 17 (9 %)
1–4 drinks/week 64 (34 %)
≥ 5 drinks per wk 18 (9 %)
Current sexual intercourse
< 1 week 42 (23 %)
1–2 times/week 96 (52 %)
≥ 3 times/week 48 (26 %)
y years, GA gestational age, wk weeks, g grams
aData represents median (interquartile range; range) or N (%), as appropriate
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Detection rates for M. hominis and M. genitalium
were much lower than for Ureaplasma spp. and Can-
dida spp. M. hominis detection rates ranged from 8 to
11 % over the three sampling points, whilst for M. geni-
talium, rates ranged from 2 to 3 % (Table 2).
Comparison of culture and real-time PCR for detection of
Ureaplasma spp.
Detection rates of Ureaplasma spp. by 10B broth culture
at 37 °C (5 % CO2, 95 % N2) were almost identical to de-
tection rates by real-time PCR. Concordance between
the two techniques was 99, 100 and 100 % over the three
time-points, respectively.
High-resolution melt PCR genotyping of U. parvum
HRM PCR was able to resolve singular U. parvum geno-
types in 91 % of colonised clinical samples. U. parvum
genotype SV6 was the most common detected, closely
followed by SV3, SV1 and SV6.1, respectively. No cases
of genotype SV14 were found (Table 2). An additional
3 % of cases were resolved to the ‘mixed’ genotype level,
suggesting the presence of two or more U. parvum ge-
notypes within the same sample. There was also a small
number of cases where either amplification was too
weak to produce a melt curve sufficient for genotype
discrimination (1 %) or no amplification was produced
whatsoever (3 %). In addition, for one study participant,
all three samples produced slightly different HRM
curves, which upon DNA sequencing, showed four
unique nucleotide polymorphisms within the targeted
region of the multiple-banded antigen gene, not indica-
tive of any of the four characterised U. parvum geno-
types. The sequence was most closely matched to
genotype SV6, and as a result was deemed genotype
SV6.1.
Vaginal colonisation dynamics
Of the 191 study participants, 134 provided samples at
all three time points. In these women, detection rates for
all organisms showed minimal variance over the dur-
ation of the study (Fig. 1). M. genitalium (1.5 % at all
three points) had the lowest variance of all organisms
detected, followed by U. parvum (36.6–37.3 %), U. urea-
lyticum (9.7–11.2 %) and non-albicans/non-glabrata
Candida spp. (0.7–2.2 %), C. albicans (32.1–34.3 %) and
M. hominis (9–11.2 %), and last, C. glabrata (1.5–5.2 %).
These results are inclusive of one case where U. par-
vum/U. urealyticum was detected at recruitment sam-
pling, after which U. urealyticum was not detected again
in subsequent samples.
Similarly, there was very little variance in U. parvum
genotype detection at any of the three time points. In
nearly all cases, the genotype detected at recruitment
was maintained throughout the second and third time
points. The only exceptions were in one case where a
participant colonised by U. parvum genotype SV6 at re-
cruitment showed a mixed genotype profile at the later
time points, and in another case where mixed genotype
Table 2 Detection rates for vaginal Ureaplasma, Mycoplasma







Gestation at sampling (wk)b 21 (13–26) 29 (24–38) 36 (32–40)
Ureaplasma spp. 91 (48 %) 74 (48 %) 67 (44 %)
U. parvum 74 (39 %) 63 (41 %) 53 (35 %)
SV1 11 (5.8 %) 10 (6.5 %) 10 (6.6 %)
SV3 27 (14.1 %) 20 (13 %) 19 (12.5 %)
SV6 31 (16.2 %) 24 (15.6 %) 18 (11.8 %)
SV6.1 1 (0.5 %) 1 (0.6 %) 1 (0.7 %)
SV14 0 (0 %) 0 (0 %) 0 (0 %)
Mixed 2 (1 %) 2 (1.3 %) 3 (2 %)
Too weak to call 0 (0 %) 3 (1.9 %) 0 (0 %)
No amplification 2 (1 %)c 2 (1.3 %)c 2 (1.3 %)c
U. urealyticum 25 (13 %) 15 (10 %) 16 (11 %)
Candida spp. 73 (38 %) 53 (34 %) 52 (34 %)
C. albicans 63 (33 %) 50 (33 %) 48 (32 %)




5 (3 %) 5 (3 %) 2 (1 %)
M. hominis 21 (11 %) 12 (8 %) 16 (11 %)
M. genitalium 6 (3 %) 3 (2 %) 4 (3 %)
aDue to variations in sample compliance, apparent reductions or increases in
genotypes over the three time points are not indicative of genotype stability
brepresents median, range
cSame study participants
Fig. 1 Prevalence of Ureaplasma, Candida and Mycoplasma spp. in
vaginal swab samples from 134 women with three completed samples
taken over the course of the pregnancy. Solid black, sample time-point 1;
dark grey, sample time-point 2; light grey, sample time-point 3
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profiles were detected at all three time points. This made
it impossible to be certain that the same combination of
genotypes was present in each instance, due to the limi-
tations of the HRM assay. There were also an additional
two instances where the HRM assay failed to generate
sufficient amplification of the second sample to allow ac-
curate genotype discrimination. However, in both of
these cases, the first and third sample genotype identifi-
cations were concordant.
Association between pharmaceutical & lifestyle factors
and detection of organisms at recruitment
Based upon answers provided by 189 study participants
at recruitment (Table 3), Ureaplasma spp. and Myco-
plasma spp. were detected more frequently in women
who previously smoked (Ureaplasma spp. −37 % present
vs. 17 % absent, p = 0.002; and Mycoplasma spp. −44 %
present vs. 24 % absent, p = 0.036), and in women who
had sexual intercourse ≥ 3 times per week during preg-
nancy (Ureaplasma spp. −35 % present vs. 18 % absent,
p = 0.018; and Mycoplasma spp. −56 % present vs. 21 %
absent, p = 0.001).
Candida spp. were detected more frequently in
women who continued to smoke during their pregnancy
(Candida spp. −18 % present vs. 7 % absent, p = 0.020).
Association between vaginal microbial colonisation and
spontaneous preterm birth
Spontaneous preterm birth <37 weeks GA
The overall microbial characteristics of vaginal samples
collected during the study are provided in Table 4. Urea-
plasma spp. were detected more frequently [85 % (95 %
CI: 62–100 %) vs. 45 % (37–52 %), p = 0.006] in the
recruitment samples of women who delivered preterm
compared to those who delivered at term (Table 4). At
the species level, the presence of U. parvum was signifi-
cantly increased among PTB cases [77 % (50–100 %) vs.
36 % (29–43 %), p = 0.004]. There was a small, but sig-
nificant association between the titre of U. parvum and
PTB, with an average U. parvum titre of 106 CCU in
cases of PTB vs. 105 CCU for term cases. U. parvum ge-
notypes SV3 and SV6 were equally represented amongst
term pregnancies; however, in women who delivered
preterm, genotype SV6 was significantly more common,
present in 54 % (22–85 %) of preterm deliveries com-
pared to 15 % (10–20 %) of term deliveries (p = 0.002).
When detected alone, the presence of Candida spp.
was not associated with PTB at either the genus or spe-
cies level. However, when C. albicans was detected
alongside U. parvum a significant positive association
with PTB was observed [46 % (15–78 %) vs. 13 % (8–18 %),
p = 0.005]. This association strengthened when U. parvum
genotype SV6 was present [39 % (8–69 %) vs. 7 %
(3–11 %), p = 0.003].
There was no apparent association between presence of
Mycoplasma spp. and PTB; however, M. genitalium was
more common in the recruitment samples from women
who delivered preterm vs. at term (15 vs. 2 %, respectively)
and this result trended towards significance (p = 0.057).
Similarly, Candida spp. were also more common in the re-
cruitment samples from women who delivered preterm vs.
at term (54 vs. 36 %, respectively); however, this difference
was not statistically significant (p = 0.241).
No association was detected between PTB and the
presence of either U. urealyticum, C. albicans, C. glab-
rata, non-albicans/glabrata Candida spp. or M. hominis.
Table 3 Association between pharmaceutical/lifestyle characteristics and detection of Ureaplasma, Candida, and Mycoplasma spp. at
recruitment (n = 189)a













Current antibiotic, antifungal or
probiotic use?
1 (1 %) 7 (7 %) 0.045 3 (4 %) 5 (4 %) 0.947 1 (4 %) 7 (4 %) 1.000
Ever diagnosed with a UTI? 32 (36 %) 43 (43 %) 0.296 30 (41 %) 45 (39 %) 0.789 8 (32 %) 67 (41 %) 0.387
Ever diagnosed with thrush? 40 (46 %) 51 (51 %) 0.448 34 (47 %) 57 (49 %) 0.798 10 (42 %) 81 (49 %) 0.479
Current smoker? 13 (15 %) 8 (8 %) 0.149 13 (18 %) 8 (7 %) 0.020 5 (20 %) 16 (10 %) 0.165
Previous smoker? 33 (37 %) 17 (17 %) 0.002 22 (31 %) 28 (24 %) 0.351 11 (44 %) 39 (24 %) 0.036
Currently consumes alcohol? 1 (1 %) 3 (3 %) 0.624 2 (3 %) 2 (2 %) 0.642 1 (4 %) 3 (2 %) 0.438
Previously consumed alcohol? 48 (54 %) 60 (61 %) 0.355 39 (53 %) 69 (60 %) 0.374 14 (56 %) 94 (58 %) 0.875
Current frequency of sexual
intercourse?
< 1 week 20 (23 %) 22 (23 %) 0.018 14 (20 %) 28 (24 %) 0.715 3 (12 %) 39 (24 %) 0.001
1–2 times/week 38 (43 %) 58 (60 %) 37 (52 %) 59 (51 %) 8 (32 %) 88 (55 %)
≥ 3 times/week 31 (35 %) 17 (18 %) 20 (28 %) 28 (24 %) 14 (56 %) 34 (21 %)
awk week; bold type indicates statistical significance (p < 0.05)
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Spontaneous preterm birth <34 weeks GA and
birthweight <1500 g
Five babies were born <34 weeks GA, including two
weighing <1500 g (Table 5). U. parvum was detected at
recruitment in all cases and in 80 % (4/5) of these, geno-
type SV6 was present. In the four earliest preterm deliv-
eries (25.9–31.4 weeks GA), both U. parvum and C.
albicans were detected at recruitment (Table 5). Unfor-
tunately, due to insufficient numbers, no statistical ana-
lyses were able to be performed on risk of PTB <34
weeks GA.
Discussion
Numerous previous studies have described an associ-
ation between detection of Ureaplasma spp. in the va-
gina during pregnancy and subsequent PTB [1].
Consistent with data from the majority of these studies,
our findings confirm a significant association between
vaginal colonisation by Ureaplasma spp. and PTB risk.
However, unlike the vast majority of previous research,
we have further discriminated between human Urea-
plasmas at the species level. Our finding that vaginal
colonisation by U. parvum, but not U. urealyticum, was
associated with an increased risk of PTB, compared to
colonisation by Ureaplasma spp. in general, highlights
a major limitation in these previous studies. This is
despite the fact that in 1990 U. urealyticum was classi-
fied as two distinct biovars, parvo (U. parvum) and
T960 (U. urealyticum) [27], and then formally proposed
as two separate species in 2002 [28]. In addition, spe-
cies (biovar)-level PCR detection assays have been
available since 1993 [29]; hence, the ability to study this
organism at the species level has existed for many
years. It is important that future studies ensure that
species-level analyses are carried out, especially those
examining pregnancy outcome, as our data showed that
U. parvum confers the greatest risk of PTB. This is in
stark contrast to other disease phenotypes, such as pel-
vic inflammatory disease [8], endometritis [8], non-
gonococcal urethritis [8–10, 12] and post-gonococcal
urethritis [11], where U. urealyticum has been reported
to be significantly associated with disease, but not U.
parvum. In previous studies [30–45] that examined the
obstetric consequences of vaginal colonisation by Urea-
plasma spp., where there were defined case and control
groups, only three discriminated between U. parvum
and U. urealyticum. Similar to our study, the two most
recent of these, Mitsunari et al. [32] and Kataoka et al.
[42] reported that vaginal colonisation by U. parvum,
but not U. urealyticum, was significantly associated
with PTB. However, in contrast, a study from the late
1990s by Abele-Horn et al. [34] came to the opposite
conclusion, with U. urealyticum apparently having
more adverse effects on birth weight, gestational age
and preterm delivery compared to U. parvum. These
are the only authors, to our knowledge, that have re-
ported an association between U. urealyticum and PTB;
however, they employed a unique set of inclusion criteria
whereby women were recruited who were solely colonised
with Ureaplasma spp. and no other ‘abnormal’
microorganisms, including C. albicans, Gardnerella
vaginalis and many others. This may have introduced
confounders.
Table 5 Detection of organisms at recruitment and birth characteristics for babies born spontaneously at <34 weeks GA (n = 5)a
GA (wk) BW (g) Sex U. parvum Titre (CCU – 10^) U. parvum/U. urealyticum U. parvum SV6 C. albicans M. hominis M. genitalium
25.9 690 M ✓ 6 U. parvum ✓ ✓ ✓ ✓
28.0 760 M ✓ 7 U. parvum ✓ ✓ - -
30.9 1560 M ✓ 6 U. parvum - ✓ ✓ -
31.4 1950 M ✓ 5 Both ✓ ✓ - ✓
32.0 1820 F ✓ 6 U. parvum ✓ - - -
awk weeks, g grams, CCU colour changing units; a tick (✓) represents presence of organism, a dash (−) absence of organism
Table 4 Vaginal colonisation rates of Ureaplasma, Candida and
Mycoplasma spp. at recruitment in women who delivered






Ureaplasma spp. 11 (85 %) 78 (45 %) 0.006
U. parvum 10 (77 %) 63 (36 %) 0.004
U. urealyticum 2 (15 %) 23 (13 %) 0.687
Titre (CCU) of U. parvumb 6 (5–6;3–7) 5 (4–6;2–8) 0.043
Serovar 3 of U. parvum 3 (23 %) 23 (13 %) 0.399
Serovar 6 of U. parvum 7 (54 %) 26 (15 %) 0.002
Candida spp. 7 (54 %) 63 (36 %) 0.241
C. albicans 6 (46 %) 55 (32 %) 0.358
C. glabrata 1 (8 %) 9 (5 %) 0.522
Non-albicans/non-glabrata 0 4 (2 %) 1.000
Mycoplasma spp.
M. hominis 2 (15 %) 19 (11 %) 0.644
M. genitalium 2 (15 %) 4 (2 %) 0.057
U. parvum + C. albicans 6 (46 %) 22 (13 %) 0.005
U. parvum serovar 6 + C. albicans 5 (39 %) 12 (7 %) 0.003
aBold type indicates statistical significance (p < 0.05)
bmedian, interquartile range, range
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We have previously discussed the history and limita-
tions associated with serotyping/genotyping of U. par-
vum and U. urealyticum [23]. As a result of this, we
developed a HRM PCR assay capable of detecting the
four genotypes of U. parvum directly from clinical sam-
ples and suggested that this assay may provide valuable
information relating to U. parvum genotype status and
specific clinical conditions [23]. In the current study,
using this assay, we were able to identify single U. par-
vum genotypes from 91 % of colonised samples, with a
further 3 % resolved to the level of ‘mixed’ genotypes.
From 74 U. parvum positive samples, we identified ge-
notypes SV6 (42 %) and SV3 (36 %) as the most com-
mon, followed by SV1 (15 %). This genotype distribution
is slightly different to that described by Xiao et al. [8],
who reported that in 169 vaginal samples from healthy
pregnant women, SV3 (63 %) was the most common,
followed by SV6 (30 %), SV1 (24 %) and SV14 (4 %).
This may indicate that the geographical location of the
cohort influences serovar prevalence. Unfortunately,
these authors did not provide any data on potential asso-
ciations between genotype and adverse pregnancy out-
come. However, in another sample set from the same
study, Xiao et al. [8] reported a significant association
between detection of U. parvum genotype SV6 in pla-
cental tissue and histologic chorioamnionitis, a condition
that is indicative of infection-associated PTB. This cor-
roborates our finding of a significant association be-
tween detection of U. parvum genotype SV6 in the
vagina and PTB <37 weeks GA, in addition to our detec-
tion of this genotype in 4/6 cases of PTB <34 weeks GA.
To our knowledge, the only other study that has ex-
amined U. parvum genotypes present in vaginal samples
is that of De Francesco et al. [46], who collected cervical,
urethral, and vaginal swabs from 806 women. In contrast
to our results, these authors reported that genotypes
SV3 and SV14 (not separated beyond this level) and SV1
were the most common detected, representing 39 and
37 % of the 158 women who were positive for Urea-
plasma spp. Genotype SV6 was detected in 24 % of
cases and was apparently associated with a vaginal
microbiota deemed ‘normal’, compared to that associated
with SV3/SV14, which was linked to an absence of lacto-
bacilli. However, it is difficult to compare these results
to those from our study, as De Francesco et al. [46] did
not differentiate the patient type associated with positive
samples, instead compiling women from outpatients for
gynaecological health care control, routine screening for
pregnancy, infertility problems and those with symptoms
of genital infections into one group. As such, the mul-
tiple phenotypes present make it impossible to extrapo-
late phenotype-specific data from this study.
Another study that examined U. parvum genotype dis-
tribution was by Sung et al. [47] and involved preterm
neonates with bronchopulmonary dysplasia (BPD). It re-
ported that SV3 and SV6, either alone or together,
accounted for 96 % of U. parvum isolates detected in
endotracheal and/or nasopharyngeal aspirates. However,
these authors failed to find an association between geno-
type and the development of moderate to severe BPD.
Also of interest, and particularly relevant to the clin-
ical use of our HRM assay, we noted that U. parvum
genotype colonisation in our study was typically singular
and in nearly all cases was stable throughout pregnancy.
Although we are unable to compare this to the work of
any previous studies due to omission of details relating
to single/multiple genotype detection [46] or presenting
multiple genotype data including U. urealyticum geno-
types [8, 47], it is interesting to note that studies that
have looked at U. urealyticum genotype distribution
generally report that when detected, multiple genotypes
are typically present [8, 47, 48]. However, this may also
be a result of problems with cross-reactivity associated
with PCR assays for these genotypes [8].
We did not detect a significant association between
the presence of vaginal Candida spp. alone and PTB, a
result that contradicts four previous studies [4–7] and a
recent systematic review [49], although we did observe a
trend towards significance. This warrants further investi-
gation in a larger cohort of women. However, when vagi-
nal colonisation by U. parvum was accompanied by C.
albicans (the most commonly detected Candida spp. in
our study), the odds ratio (OR) for risk of PTB increased
marginally from 3.32 (U. parvum alone) to 3.77 (both
organisms). Stratifying U. parvum by genotype, add-
itional increases in risk were seen when C. albicans was
combined with U. parvum genotype SV6, with the OR
rising from 4.17 to 5.16. Both organisms have previously
been associated with increased PTB risk [1, 5, 50], while
colonisation of amniotic fluid by C. albicans has been
linked to severe fetal injury [51–53]; however, no previ-
ous studies have looked at the effects of combined
asymptomatic vaginal colonisation and pregnancy out-
come, particularly regarding U. parvum genotype. Fur-
ther research is warranted, firstly to confirm our novel
findings in a larger cohort, and second to attempt to un-
cover what factors may be responsible for this associ-
ation. If our findings are confirmed, then detection of
these two organisms during the early second trimester
of pregnancy could prove to be a useful indicator of
women at a high risk of infection-associated PTB and
therefore targets for antimicrobial therapy.
Although we have discussed the results of our study in
terms of presence/absence of specific bacteria at ~21
weeks GA (primarily as this is of major relevance to
allow implementation of suitable treatment regimens for
prevention of PTB), our study also examined vaginal
samples at two additional time points (~28 weeks and
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~36 weeks GA). To the best of our knowledge, this is
the first study to examine the dynamics of Ureaplasma
spp., Mycoplasma spp. and Candida spp. throughout the
second and third trimesters of pregnancy. We demon-
strated that detection of all organisms (with the excep-
tion of C. glabrata) was very stable throughout the three
sampling points, particularly so for M. genitalium and
U. parvum. In addition, for U. parvum we also demon-
strated that in nearly all cases, the genotype detected at
recruitment was maintained throughout the second
and third time points. These are very important find-
ings as they demonstrate that detection of these organ-
isms early in the second trimester of pregnancy is
highly predictive of their presence both early and late
in the third trimester, and provides valuable informa-
tion for future diagnostic assays aiming to predict
women at risk of PTB.
Of significant relevance to use of U. parvum detection
assays in future clinical diagnostic applications, we
showed near 100 % concordance between detection of
Ureaplasma spp. in clinical samples using either
culture-based or PCR methods, in contrast to some pre-
vious authors who reported disparities between the two
techniques [54–56]. It has been well established that
Ureaplasma sp. cells are fragile and in order to optimise
recovery from clinical samples, special attention needs
to be paid to sample collection, storage and transporta-
tion, in addition to the media used for culture [57]. Our
results are most likely a reflection of our highly stringent
sample collection and culture conditions, whereby swabs
were immediately placed into UTM media, stored at 4 °
C and cultured in 10B broth within 24 h of collection
under microaerophilic conditions. This is important, as
despite the increased use of molecular methods for de-
tection of Ureaplasma spp., culture is likely to play a
key role alongside these in future studies attempting to
document virulence traits of strains associated with spe-
cific disease phenotypes.
In addition to culturing Ureaplasma spp. from our
clinical samples, we also documented the titre of organ-
isms present in each. We identified a small, but signifi-
cant association between the titre of U. parvum and
PTB, with an average U. parvum titre of 106 CCU in
cases of PTB vs. 105 CCU for term cases. Although this
may appear significant statistically, it is unlikely to be
clinically relevant. We used eight 10-fold serial dilu-
tions of 10B broth culture for quantitation and
expressed our titres in colour changing units (CCU), a
technique that has been widely used in Ureaplasma sp.
culture [58–61]. A limitation of the CCU method is
that although it is far more suited to quantitation of
large sample numbers, it really is semi-quantitative in
that the titre values obtained actually represent a range
rather than hard values. For instance, 106 CCU may
actually be 1,000,000–9,000,000 cells. As a result, we
believe clinical significance would have only been justi-
fied in the case of a difference of two dilution series, as
opposed to a single series, such as we observed. Stand-
ard solid agar plate quantitation methods are not well
suited to Ureaplasma spp. due to the tiny colony size
and associated quantitation difficulties (a microscope
with ~ 10–40× magnification is required). Despite this,
Abele-Horn et al. [35] used this method for quantita-
tion and following multivariate analysis of 172 Urea-
plasma-colonised and 123 non-colonised pregnant
women, they reported that Ureaplasma sp. vaginal col-
onisation was an independent risk factor for PTB at
105 CFU/mL and for chorioamnionitis at both 104–105
and 105 CFU/mL. Lower colonisation levels had no ad-
verse effects on pregnancy outcome [35]. Regardless of
the method used though, it could be argued that accur-
ate quantitation of any bacteria from a swab-collected
sample is confounded by the manner of sample collec-
tion, which is likely to have a large effect on the results.
Although our sample size was too small to accurately
document any association between detection of vaginal
M. genitalium and PTB, we observed a trend towards
significance, with detection rates of 12 and 2 % at re-
cruitment in women delivering preterm and term, re-
spectively. This result is particularly interesting in that it
conflicts with the findings of four previous studies, all of
which found no association between vaginal M. genita-
lium and PTB; interestingly, they reported detection
rates (0.7–8 %) somewhat lower than those reported
here [62–65]. One of these was by Labbe et al. [65] who
reported rates of 8 % in preterm deliveries (16/183) and
6 % in women delivering at term (36/564) in a popula-
tion of women from a developing country, many of
whom also screened positive for other known sexually
transmitted infections, including human immunodefi-
ciency virus (HIV). In comparison, Hitti et al. [66], re-
ported detection rates of only 4 % (29/661) and 2 % (12/
667) in Peruvian women who delivered preterm and
term, respectively. This finding was significant, accom-
panied by an odds ratio of 2.5 (95 % CI: 1.2–5.0). Of par-
ticular interest, both Oakeshott et al. [63] and Hitti et al.
[66] documented that vaginal M. genitalium was more
commonly observed in women of a younger maternal
age (<20 years and mean 21.2 years, respectively). This
was also true in our cohort, where the mean age of
women in which vaginal M. genitalium colonisation was
detected was 24.3 years (in comparison to the overall co-
hort mean age of 30), and perhaps suggests that mater-
nal age needs to be taken into account when assessing
microbiological-associated PTB risk.
Many previous studies that have examined associations
between vaginal bacterial colonisation and PTB have not
considered the effect of lifestyle factors on the species
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present. By administering questionnaires to our partici-
pants at each sampling point (asking about such lifestyle
factors as smoking before/during pregnancy and the
amount of sexual intercourse during pregnancy), we
sought to establish if there was a relationship between
these factors and organism presence. For both Urea-
plasma spp. and Mycoplasma spp., we observed signifi-
cantly higher detection rates in women who reported
having sexual intercourse greater than or equal to 3
times per week during the course of their pregnancy.
Considering that both of these organisms are known
colonisers of both the female and male genital tracts
[67], and are also considered sexually-transmitted infec-
tions in certain circumstances [20], this result is not sur-
prising. However, of particular interest, we also observed
associations between women who either smoked prior to
or during their pregnancy and increased detection rates
of Ureaplasma, Mycoplasma and/or Candida spp. Of
statistical significance, higher detection rates of Urea-
plasma spp. (37 vs. 17 %) and Mycoplasma spp. (44 vs.
24 %) were observed in women who smoked prior to
their pregnancy and for Candida spp., colonisation rates
were significantly higher in women who continued to
smoke throughout their pregnancy (18 vs. 7 %). A simi-
lar phenomenon has been reported previously in relation
to smoking and vaginal microbiology in the case of hu-
man papillomavirus (HPV) infection [68] and also for
bacterial vaginosis [15]. Although the association be-
tween BV and smoking may help to explain the associ-
ation between Ureaplasma spp. and Mycoplasma spp.,
both of which have been previously reported as BV-
associated agents [3], Candida spp. are not typically as-
sociated with BV. In addition, whereas it has been re-
ported that the anti-estrogenic effect of smoking [69]
may predispose a woman to BV [16], it has been previ-
ously documented that Candida spp. are more prevalent
during pregnancy as a result of the increased amounts of
estrogen present [70]. One possible explanation could be
that benzo[a]pyrene, found in trace amounts in the vagi-
nal secretions of smokers, has been shown to signifi-
cantly induce Lactobacillus spp. prophages [71]. This
would result in a decrease in numbers of vaginal Lacto-
bacillus spp. due to cell lysis from lytic phages, poten-
tially providing a more favourable environment for
Candida spp. and especially BV-associated organisms, as
Lactobacillus spp. are critical for maintenance of an
acidic vaginal pH [72]. Detailed metagenomics studies
would be required to address this hypothesis.
Conclusions
Although many previous studies have shown associa-
tions between Ureaplasma spp. and PTB, our study has
demonstrated the importance of detecting U. parvum
and U. urealyticum as individual species, and for U.
parvum, genotype, when investigating the relationship
between vaginal colonisation and PTB risk. We found
that vaginal U. parvum colonisation was associated with
increased risk of spontaneous PTB, and that detection of
U. parvum genotype SV6 was of even higher signifi-
cance, especially when combined with the presence of C.
albicans. This result now needs to be confirmed in a lar-
ger cohort of women, preferably in both similar and dif-
ferent ethnic populations, in order to evaluate its use as
an early detection biomarker for risk of PTB. Our
finding that colonisation status is preserved across preg-
nancy is clinically important, suggesting that for Urea-
plasma, Mycoplasma and Candida spp., a single sample
taken in pregnancy has diagnostic and prognostic utility.
The cause and effect relationships between colonisation
with U. parvum genotype SV6, C. albicans and preterm
labour, however, are unproven. Further work is currently
underway to attempt to identify potential virulence fac-
tors at the genome level, in addition to describing the re-
lationship between vaginal colonisation and intraamniotic
infection with specific organisms in order to illuminate a
plausible mechanism. Lastly, our finding that smoking
either prior to pregnancy or during pregnancy is signifi-
cantly associated with Ureaplasma, Mycoplasma and
Candida spp. vaginal colonisation status offers additional
insight into relationships between lifestyle and pregnancy
risk. Larger studies are needed to confirm these findings
in cohorts of past and current smokers.
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